Drug delivery to the posterior segment of the eye.
Drug delivery into the posterior segment of the eye is complicated by the existence of the blood-ocular barrier. Strategies for delivering drugs to the posterior segment include systemic administration, modification of the barrier, and local drug delivery (including transcorneal, transscleral, and intravitreal). Recently, new topical treatments have emerged for the treatment of posterior eye disease. Iontophoretic, juxtascleral, and intravitreal routes can be used to achieve therapeutic levels in the posterior segment. Extended-release intravitreal drug delivery systems can achieve sustained therapeutic levels with the goal of providing a prolonged clinical benefit.
Kuppermann
Baruch D
BD
Loewenstein
Anat
A
D018916:Blood-Aqueous Barrier / Q000187:drug effects / Q000502:physiology*; D016503:Drug Delivery Systems / Q000295:instrumentation*; D004867:Equipment Design; D005901:Glaucoma / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy* / Q000378:metabolism; D057972:Posterior Eye Segment / Q000187:drug effects* / Q000378:metabolism